1. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic
- Author
-
Priscilla K, Brastianos, Erin L, Twohy, Elizabeth R, Gerstner, Timothy J, Kaufmann, A John, Iafrate, Jochen, Lennerz, Suriya, Jeyapalan, David E, Piccioni, Varun, Monga, Camilo E, Fadul, David, Schiff, Jennie W, Taylor, Sajeel A, Chowdhary, Chetan, Bettegowda, George, Ansstas, Macarena, De La Fuente, Mark D, Anderson, Nicole, Shonka, Denise, Damek, Jose, Carrillo, Lara J, Kunschner-Ronan, Rekha, Chaudhary, Kurt A, Jaeckle, Francis M, Senecal, Thomas, Kaley, Tara, Morrison, Alissa A, Thomas, Mary R, Welch, Fabio, Iwamoto, David, Cachia, Adam L, Cohen, Shivangi, Vora, Michael, Knopp, Ian F, Dunn, Priya, Kumthekar, Jann, Sarkaria, Susan, Geyer, Xiomara W, Carrero, Maria, Martinez-Lage, Daniel P, Cahill, Paul D, Brown, Caterina, Giannini, Sandro, Santagata, Frederick G, Barker, and Evanthia, Galanis
- Abstract
Patients with progressive or recurrent meningiomas have limited systemic therapy options. Focal adhesion kinase (FAK) inhibition has a synthetic lethal relationship withEligible patients whose tumors screened positively forOf 322 patients screened for all mutation cohorts of the study, 36 eligible and evaluable patients withGSK2256098 was well tolerated and resulted in an improved PFS6 rate in patients with recurrent or progressive
- Published
- 2022